General Dermatology

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Dermatology undergoes rapid transformation with new therapies, but faces challenges in payment reform, certification awareness, and balancing technology with patient care.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Paller discusses the promising phase 3 trial SELVA trial results for Qtorin 3.9% rapamycin gel, an investigative treatment for microcystic lymphatic malformations.

Complete remission was achieved in over 87% of dupilumab users and 64% of omalizumab users.

This review of the latest dermatologic studies includes insights into epidermolysis bullosa for primary care providers, patient-reported impact of atopic dermatitis on pediatric and adolescent patients, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Palvella has secured its 5th US patent for Qtorin rapamycin, extending intellectual property coverage to 2038 and advancing treatment for microcystic lymphatic malformations.

A survey by LEO Pharma indicates widespread misunderstandings about chronic hand eczema, revealing significant emotional and occupational challenges for patients.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Explore the top headlines of the week including insights on the latest clinical trials, therapeutic updates, and more.

Test your knowledge of key words and terms associated with dermatology news from the previous week.

In case you missed it, this week we had news about HyBryte's treatment success in CTCL patients, the impact of the COVID-19 pandemic on BCC surgeries, the FDA approval of dupilumab for H1 antihistamine-refractory CSU, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Dupilumab becomes the first targeted therapy approved for chronic spontaneous urticaria in more than a decade.

Spearheaded by John Zampella, MD, FAAD, and Mitchell Hanson, the project highlights how art can foster community and empathy in dermatology.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Pelthos and Channel Therapeutics will merge to form a new publicly traded entity focused on commercializing the first at-home treatment for molluscum.

Haut.AI’s new tool promotes inclusive and realistic conversations on the power of skincare products, according to the CEO.

From our April issue: Unlock exclusive AAD 2025 insights from top dermatology experts—what you missed and what’s next.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

This review of the latest dermatologic studies includes insights into dermatologic associations in patients with Crohn disease, the prevalence of tinea pedis in pediatric populations, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Evommune has initiated a global phase 2b trial of EVO756, a first-in-class MRGPRX2 antagonist, for moderate to severe CSU.

In a large study, nearly half of SIND patients also had other BFRBs like skin picking or hair pulling.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Interim FDA-funded study results show HyBryte delivers rapid, sustained response and strong safety in early-stage CTCL patients.

Explore the top headlines of the week including insights on infection risks, drug updates, and more.

Test your knowledge of key words and terms associated with dermatology news from the previous week.

In case you missed it, this week we had news about Alphyn Biologics' first patient dosed with zabalafin hydrogel, abrocitinib for Netherton Syndrome, the ICONIC-LEAD phase 3 study, and more.